The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation
Clicks: 216
ID: 111531
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
213 views
22 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Natural killer (NK) cells are innate lymphocytes responsible for the elimination of infected or transformed cells. The activation or inhibition of NK cells is determined by the balance of target cell ligand recognition by stimulatory and inhibitory receptors on their surface. Previous reports have suggested that the glycosaminoglycan heparin is a ligand for the natural cytotoxicity receptors NKp30, NKp44 (human), and NKp46 (both human and mouse). However, the effects of heparin on NK cell homeostasis and function remain unclear. Here, we show that heparin does not enhance NK cell proliferation or killing through NK cell activation. Alternatively, in mice models, heparin promoted NK cell survival in vitro and controlled B16-F10 melanoma metastasis development in vivo. In human NK cells, heparin promisingly increased interferon (IFN)-γ production in synergy with IL-12, although the mechanism remains elusive. Our data showed that heparin is not able to increase NK cell cytotoxicity.
| Reference Key |
rossi2020journalthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Gustavo R. Rossi;Jenifer P. Gonçalves;Timothy McCulloch;Rebecca B. Delconte;Robert J. Hennessy;Nicholas D. Huntington;Edvaldo S. Trindade;Fernando Souza-Fonseca-Guimaraes;Rossi, Gustavo R.;Gonçalves, Jenifer P.;McCulloch, Timothy;Delconte, Rebecca B.;Hennessy, Robert J.;Huntington, Nicholas D.;Trindade, Edvaldo S.;Souza-Fonseca-Guimaraes, Fernando; |
| Journal | journal of clinical medicine |
| Year | 2020 |
| DOI |
10.3390/jcm9082666
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.